Updated Guidance for Healthcare Providers on Increased Supply of Nirsevimab to Protect Young Children from Severe Respiratory Syncytial Virus (RSV) during the 2023–2024 Respiratory Virus Season — On October 23, 2023, the Centers for Disease Control and Prevention (CDC) issued Health Alert Network (HAN) Health Advisory 499 to provide guidance for prioritization of nirsevimab given limited supply. Nirsevimab (Beyfortus, Sanofi and AstraZeneca) is a long-acting monoclonal antibody immunization recommended for preventing RSV-associated lower respiratory tract disease in young children.
Given the recent increase in nirsevimab supply and the manufacturers’ plan to release an additional 230,000 doses in January, CDC advises healthcare providers to return to recommendations put forward by CDC and the Advisory Committee on Immunization Practices (ACIP) on use of nirsevimab in young children. Infants and children recommended to receive nirsevimab should be immunized as quickly as possible. Healthcare providers should not reserve nirsevimab doses for infants born later in the season when RSV circulation and risk for exposure to RSV may be lower. To learn more, please visit: CDC Clinician Outreach and Communication Activity
Weekly Viral Respiratory Illness Snapshot (updated on Fridays) — Seasonal influenza activity is elevated and increasing in most parts of the country. COVID-19 activity remains elevated overall and is increasing in many areas. The U.S. continues to experience elevated RSV activity, particularly among young children. Hospital bed occupancy for all patients, including within intensive care units, remains stable nationally. To learn more, please visit: Weekly Viral Respiratory Illness Snapshot (cdc.gov)
BriggsNetNews 